Isotechnika's ISAtx247 molecule is being tested on psoriasis. The web cast on their web site( www.isotechnika.com ) shows before and after shots of patients with severe psoriasis. The results appear spectacular, showing patients being cleared up after 3 weeks of treatment. The web cast also shows that ISAtx247 is the first immunosuppressant to have a large therapeutic window. Early indications look like ISAtx247 will become the gold standard drug for organ transplants and also for treating autoimmune diseases like psoriasis, and potentially, other autoimmune diseases like Rheumatoid Arthritis, Crones, Lupis, and type 1 diabetes.
Also, ISA recently completed a huge partnering deal with Roche on this molecule.
Message 17304260
As important as the partnering deal is, I believe the big picture is that ISA has patented certain aspects of AST (atomic substitution technology) used in ISA's proprietary method of re designing and improving gold standard drugs. ISA appears to have a drug development platform that uses deuteration to target various sites of re designed drug molecules to increase the potency of drugs, reduce toxicity of the drugs, reduce the clearance of the pharmacologically active moiety and improve the stability of drug molecules. ISA then determines the physicochemical, toxicological and pharmacokinetic properties by using standard chemical and biological assays and through the use of mathematical modeling techniques which are known in the chemical and pharmacological/toxicological arts. The therapeutic utility and dosing regimen is then extrapolated from the results of such techniques and through the use of appropriate pharmacokinetic and/or pharmacodynamic models.
ISA's drug drug development model/methodology seems to effectively screen new drugs before entering human trials, resulting in decreased time, lower risk and cost and increased rate of molecules entering a "new drug pipeline". Reading between the lines, ISA's proprietary drug development methods could in theory be used to target every top selling, gold standard drug (on or off patent) of all the big pharmas. ISA's drug development system could be a serious threat to the business model of all the large pharmas. I believe this company has the potential to be a monster hit. |
